MiNK Therapeutics reported financial results for the quarter ended June 30, 2026. Cash and cash equivalents were $8.8 million as of June 30, 2026. Net loss was $3.1 million, or $0.62 per share, compared with a net loss of $4.2 million, or $1.06 per share, for the second quarter of 2025. For the six months ended June 30, 2026, net loss was $5.9 million, or $1.20 per share. The company initiated dosing in its randomized Phase 2 trial C-1300-02 for agenT-797 in acute lung injury and ARDS in Ukraine. Initial Day 28 observations showed improved oxygenation and liberation from ventilator support with no major serious adverse events attributed to the therapy. MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders.